{"id":"acetylsalicyclic-acid-asa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal upset"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"1-5%","effect":"Renal impairment"},{"rate":"1-5%","effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL374385","moleculeType":"Small molecule","molecularWeight":"331.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to a decrease in the production of prostaglandins, which are mediators of inflammation and pain, and thromboxanes, which are involved in blood clotting. As a result, ASA has anti-inflammatory, analgesic, and antiplatelet effects.","oneSentence":"Acetylsalicylic acid (ASA) works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:51.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cardiovascular thrombotic events in patients at risk of myocardial infarction or stroke, including those with a history of myocardial infarction, stroke, transient ischemic attack, or coronary artery bypass graft surgery"},{"name":"Relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT04142125","phase":"PHASE3","title":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-02-03","conditions":"Ischemic Stroke, Intracranial Atherosclerotic Disease","enrollment":101},{"nctId":"NCT01122602","phase":"PHASE3","title":"Evaluate Analgesic Efficacy of Fast Release Aspirin","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04-29","conditions":"Drugs, Investigational","enrollment":500},{"nctId":"NCT01420094","phase":"PHASE3","title":"Evaluate Onset of Action of a Fast Release Aspirin","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-16","conditions":"Healthy Subjects","enrollment":510},{"nctId":"NCT00178464","phase":"PHASE1","title":"Aspirin Prophylaxis in Sickle Cell Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-03","conditions":"Sickle Cell Disease","enrollment":11},{"nctId":"NCT02612480","phase":"NA","title":"Ticagrelor in Human Endotoxemia Response to Human Endotoxemia","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-10","conditions":"Endotoxemia","enrollment":40},{"nctId":"NCT00249873","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Atrial Fibrillation, Vascular Risk","enrollment":7554},{"nctId":"NCT00335452","phase":"PHASE3","title":"Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Acute Coronary Disease, Angina Unstable","enrollment":25086},{"nctId":"NCT00331786","phase":"PHASE1","title":"Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2006-07","conditions":"Colorectal Cancer","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aspirin"],"phase":"phase_3","status":"active","brandName":"acetylsalicyclic acid (ASA)","genericName":"acetylsalicyclic acid (ASA)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetylsalicylic acid (ASA) works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes. Used for Prevention of cardiovascular thrombotic events in patients at risk of myocardial infarction or stroke, including those with a history of myocardial infarction, stroke, transient ischemic attack, or coronary artery bypass graft surgery, Relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}